{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:57:23Z","timestamp":1785275843006,"version":"3.55.0"},"reference-count":72,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PPA"],"DOI":"10.2147\/ppa.s311836","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T23:45:16Z","timestamp":1621554316000},"page":"1061-1073","source":"Crossref","is-referenced-by-count":8,"title":["Adult Patient Preferences for Long-Acting ADHD Treatments: A Discrete Choice Experiment"],"prefix":"10.2147","volume":"Volume 15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0061-104X","authenticated-orcid":true,"given":"M Janelle","family":"Cambron-Mellott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaromir","family":"Mikl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana E","family":"Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0259-7122","authenticated-orcid":true,"given":"Jennifer G","family":"Erensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Beusterien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1918-8130","authenticated-orcid":true,"given":"Marc J","family":"Cataldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Hallissey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory W","family":"Mattingly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,5]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s12402-016-0208-3","volume":"9","author":"Fayyad","year":"2017","journal-title":"Atten Defic Hyperact Disord"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1471-244X-10-67","volume":"10","author":"Kooij","year":"2010","journal-title":"BMC Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2045125317734977","volume":"8","author":"Geffen","year":"2018","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/eb-2016-102415","volume":"20","author":"De Crescenzo","year":"2017","journal-title":"Evid Based Ment Health"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4172\/2327-5146.1000313","volume":"21","author":"Briars","year":"2016","journal-title":"J Pediatr Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"26S","DOI":"10.1097\/00004583-200202001-00003","volume":"41","author":"Greenhill","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref8","unstructured":"CADDRA. Canadian ADHD resource alliance (CADDRA): Canadian ADHD practice guidelines; 2020. Available from: https:\/\/www.caddra.ca\/wp-content\/uploads\/CADDRA-Guidelines-4th-Edition_-Feb2018.pdf. Accessed July 19, 2020."},{"key":"ref9","unstructured":"NICE. Attention deficit hyperactivity disorder: diagnosis and management NICE guidelines [CG72]; 2018. Available from: https:\/\/www.nice.org.uk\/guidance\/ng87. Accessed July 19, 2020."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1517\/14656566.8.6.745","volume":"8","author":"Weisler","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s12402-013-0106-x","volume":"5","author":"L\u00f3pez","year":"2013","journal-title":"Atten Defic Hyperact Disord"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.3949\/ccjm.82.s1.01","volume":"82","author":"Austerman","year":"2015","journal-title":"Cleve Clin J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1080\/00325481.2017.1354648","volume":"129","author":"Mattingly","year":"2017","journal-title":"Postgrad Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/PPA.S10647","volume":"5","author":"Brinkman","year":"2011","journal-title":"Patient Prefer Adherence"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s40271-015-0112-5","volume":"8","author":"Schatz","year":"2015","journal-title":"Patient"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40271-016-0202-z","volume":"10","author":"Ng","year":"2017","journal-title":"Patient"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/PPA.S6389","volume":"5","author":"Van Brunt","year":"2011","journal-title":"Patient Prefer Adherence"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1089\/cap.2016.0157","volume":"27","author":"DosReis","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1017\/S0266462311000249","volume":"27","author":"Lloyd","year":"2011","journal-title":"Int J Technol Assess Health Care"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00787-013-0515-6","volume":"23","author":"Nafees","year":"2014","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3109\/08039488.2012.748825","volume":"67","author":"Glenng\u00e5rd","year":"2013","journal-title":"Nord J Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40271-014-0098-4","volume":"8","author":"dosReis","year":"2015","journal-title":"Patient"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/pl00022070","volume":"14","author":"Matza","year":"2005","journal-title":"Qual Life Res"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1176\/appi.ps.201300525","volume":"66","author":"Ross","year":"2015","journal-title":"Psychiatr Serv"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1080\/15374416.2011.581617","volume":"40","author":"Waschbusch","year":"2011","journal-title":"J Clin Child Adolesc Psychol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"Bridges","year":"2011","journal-title":"Value Health"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"Johnson","year":"2013","journal-title":"Value Health"},{"key":"ref28","volume-title":"American Professional Society of ADHD and Related Disorders","year":"2020"},{"key":"ref29","unstructured":"Purdue Pharmaceuticals. Adhansia XR: highlights of prescribing information; 2019. Available from: https:\/\/app.adlontherapeutics.com\/adhansia-xr\/fpi.pdf. Accessed April 3, 2019."},{"key":"ref30","unstructured":"Shire US Inc. ADDERALL XR\u00ae: highlights of prescribing information; 2013. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021303s026lbl.pdf. Accessed November 20, 2018."},{"key":"ref31","unstructured":"Novartis Pharmaceuticals Corporation. FOCALIN XR: highlights of prescribing information; 2019. Available from: https:\/\/www.novartis.us\/sites\/www.novartis.us\/files\/focalinXR.pdf. Accessed April 8, 2019."},{"key":"ref32","unstructured":"UCB. Metadate CD: highlights of prescribing information; 2013. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021259s023lbl.pdf. Accessed April 9, 2019."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2147\/IPRP.S142576","volume":"6","author":"Caballero","year":"2017","journal-title":"Integr Pharm Res Pract"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1089\/104454603322163853","volume":"13","author":"Carlson","year":"2003","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1089\/cap.2017.0095","volume":"28","author":"Childress","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/S40263-014-0180-4","volume":"28","author":"Ginsberg","year":"2014","journal-title":"CNS Drugs"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12325-013-0085-5","volume":"31","author":"Huss","year":"2014","journal-title":"Adv Ther"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2147\/ndt.s6985","volume":"4","author":"Kolar","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/1087054712474685","volume":"21","author":"L\u00f3pez","year":"2017","journal-title":"J Atten Disord"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1080\/00325481.2016.1216716","volume":"128","author":"Stark","year":"2016","journal-title":"Postgrad Med"},{"key":"ref41","unstructured":"Shire US Inc. MYDAYIS: highlights of prescribing information; 2017. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/022063s000lbl.pdf. Accessed May 4, 2021."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1542\/peds.113.3.e206","volume":"113","author":"Swanson","year":"2004","journal-title":"Pediatrics"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1517\/14656566.6.6.1003","volume":"6","author":"Weisler","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4088\/PCC.11r01168","volume":"13","author":"Weisler","year":"2011","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/00325481.2018.1481712","volume":"130","author":"Wigal","year":"2018","journal-title":"Postgrad Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1089\/CAP.2016.0177","volume":"27","author":"Wigal","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/cap.2012.0073","volume":"23","author":"Wigal","year":"2013","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"108705471667233","DOI":"10.1177\/1087054716672335","volume":"24","author":"Wigal","year":"2016","journal-title":"J Atten Disord"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1744-9081-6-34","volume":"6","author":"Wigal","year":"2010","journal-title":"Behav Brain Funct"},{"key":"ref50","unstructured":"Shire US Inc. VYVANSE \u00ae: highlights of prescribing information; 2017. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208510lbl.pdf. Accessed November 20, 2018."},{"key":"ref51","unstructured":"Tris Pharma. QUILLICHEW ER\u00ae: highlights of prescribing information; 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/207960s005lbl.pdf. Accessed April 9, 2019."},{"key":"ref52","unstructured":"Tris Pharma. QUILLIVANT XR\u00ae: highlights of prescribing information; 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/202100s012lbl.pdf. Accessed April 9, 2019."},{"key":"ref53","unstructured":"Novartis Pharmaceuticals Corporation. Ritalin LA\u00ae: highlights of prescribing information; 2019. Available from: https:\/\/www.novartis.us\/sites\/www.novartis.us\/files\/ritalinLA_pmg.pdf. Accessed November 20, 2018."},{"key":"ref54","unstructured":"Neos Therapeutics. ADZENYS XR-ODT: highlights of prescribing information; 2016. Available from: http:\/\/www.neostxcontent.com\/Labeling\/Adzenys\/Adzenys_PI.pdf. Accessed April 9, 2019."},{"key":"ref55","unstructured":"Rhodes Pharmaceuticals. APTENSIO XR: highlights of prescribing information; 2017. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/205831s003lbl.pdf. Accessed April 8, 2019."},{"key":"ref56","unstructured":"Janssen Pharmaceuticals. CONCERTA\u00ae: highlights of prescribing information; 2013. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021121s038lbl.pdf. Accessed November 20, 2018."},{"key":"ref57","unstructured":"Tris Pharma. DYANAVEL XR: highlights of prescribing information; 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208147s002lbl.pdf. Accessed April 9, 2019."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/10401230600801077","volume":"18","author":"Adler","year":"2006","journal-title":"Ann Clin Psychiatry"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1017\/S0033291704002892","volume":"35","author":"Kessler","year":"2005","journal-title":"Psychol Med"},{"key":"ref60","unstructured":"Office of Management and Budget. Standard occupational classification manual; 2018. Available from: https:\/\/www.bls.gov\/soc\/2018\/soc_2018_manual.pdf. Accessed April 13, 2021."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1086\/691697","volume":"4","author":"Johnston","year":"2017","journal-title":"J Assoc Environ Resour Econ"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"Hauber","year":"2016","journal-title":"Value Health"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"e1350","DOI":"10.7287\/peerj.preprints.1103v3","volume":"3","author":"Dziak","year":"2015","journal-title":"PeerJ"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"American Psychological Association Presidential Task Force on Evidence-Based Practice. Evidence-based practice in psychology. Am Psychol. 2006;61(4):271\u2013285. doi:10.1037\/0003-066X.61.4.271","DOI":"10.1037\/0003-066X.61.4.271"},{"key":"ref65","unstructured":"Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. National Academies Press; 2001."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1017\/S1092852916000808","volume":"21","author":"Mattingly","year":"2016","journal-title":"CNS Spectr"},{"key":"ref67","unstructured":"Mattingly GW, Jain R, Hegarty J, O\u2019Brien Q. Investigation of clinical practice challenges in the management of ADHD. In: American Professional Society of ADHD & Related Disorders Annual Meeting; 2018."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1089\/cap.2016.0002","volume":"27","author":"Childress","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref69","unstructured":"Smith G. Does gender influence online survey participation?: a record-linkage analysis of university faculty online survey response behavior; 2008. Available from: https:\/\/scholarworks.sjsu.edu\/elementary_ed_pub. Accessed April 12, 2021."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11301-014-0111-y","volume":"65","author":"Keusch","year":"2015","journal-title":"Manag Rev Q"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/appy.12160","volume":"6","author":"Lee","year":"2014","journal-title":"Asia Pac Psychiatry"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.biopsych.2003.12.003","volume":"55","author":"Biederman","year":"2004","journal-title":"Biol Psychiatry"}],"container-title":["Patient Preference and Adherence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=69674","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=69674","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T23:45:46Z","timestamp":1621554346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/adult-patient-preferences-for-long-acting-adhd-treatments-a-discrete-c-peer-reviewed-fulltext-article-PPA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":72,"URL":"https:\/\/doi.org\/10.2147\/ppa.s311836","relation":{},"ISSN":["1177-889X"],"issn-type":[{"value":"1177-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}